Corbus Pharmaceuticals Holdings, Inc.
CRBP
$7.70
$0.141.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 7.68% | -11.76% | |||
| Gross Profit | -7.68% | 11.76% | |||
| SG&A Expenses | 25.98% | 0.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.64% | -10.04% | |||
| Operating Income | -10.64% | 10.04% | |||
| Income Before Tax | -11.74% | 11.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.74% | 11.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.74% | 11.94% | |||
| EBIT | -10.64% | 10.04% | |||
| EBITDA | -10.67% | 10.05% | |||
| EPS Basic | 1.54% | 34.25% | |||
| Normalized Basic EPS | 6.54% | 30.73% | |||
| EPS Diluted | 1.54% | 34.25% | |||
| Normalized Diluted EPS | 6.54% | 30.73% | |||
| Average Basic Shares Outstanding | 13.49% | 33.93% | |||
| Average Diluted Shares Outstanding | 13.49% | 33.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||